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1. Introduction 
Type 2 diabetes mellitus (T2DM) is increasing in prevalence worldwide, and is expected to 
affect 440 million people by 2030 (IDF, 2009). Despite the development and use of several 
medications to control patients’ blood glucose levels, the effective management of T2DM 
continues to be a challenge to physicians. In order to achieve HbA1c targets (<7.0%), 
patients must reach desirable fasting (90 mg/dL - 130 mg/dL) and postprandial glucose 
levels (<180 mg/dL) (American Diabetes Association, 2006). However, two thirds of patients 
with T2DM remain unable to reach the HbA1c targets (Koro, 1988; Fan, 2006).  
Blood glucose levels are dependent on the dynamic processes of hepatic production of 
glucose and skeletal muscle use of glucose. Treatment strategies designed to improve these 
processes have as a result the improvement in patient’s glycemic status. Different agents are 
currently available, providing physicians with several options for the management of 
T2DM. These clinical therapies include insulin and oral drugs that are classified as insulin 
sensitizers (e.g., biguanides and thiazolidinediones), insulin secretagogues (e.g., 
sulfonylureas and meglitinides), and alpha-glucosidase inhibitors. Newer treatment agents, 
incretin mimetics and dipeptidyl peptidase 4 (DPP-4) inhibitors, have been recently added 
to clinicians’ therapeutic choices (Drucker, 2003; Drucker, 2006a). 
2. The incretin effect 
The concept that gut factors stimulate pancreatic endocrine secretion was hypothesized soon 
after secretin was discovered in 1902 (Kieffer, 1999). In 1906, this notion was tested by giving 
gut extracts to patients with diabetes, which reduced their glycosuria (Moore, 1906). In the 
1920s, based on studies in dogs, the term incretins was introduced for the gastrointestinal 
hormones released in response to food ingestion (Zunz, 1929). These hormones are 
responsible for approximately 60% of the insulin secretion following a meal and for the so-
called incretin effect. The incretin effect describes the phenomenon that oral glucose leads to 
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a greater insulin response than an isoglycaemic intravenous glucose load (McIntyre, 1964; 
Nauck, 1986).  
There are two major incretins: glucosedependent insulinotropic polypeptide (GIP) and 
glucagon-like peptide 1 (GLP-1). In this chapter we will focus on GLP-1 actions, since this 
molecule is preserved in patients with T2DM. 
3. Physiological actions of GLP-1 
GLP-1 is a product of the glucagons gene, which is expressed in pancreatic ǂ-cells and in L-
cells, located mostly in the lower small intestine and colon. GLP-1 concentrations increase as 
early as 5 to 10 minutes following ingestion of carbohydrates and lipids, well before the 
nutrients pass into the lower gut where most L-cells are located (Eissele, 1992; Deacon, 
1995). Once released from L- cells, GLP-1 is rapidly metabolized by a widely distributed 
serine protease, DPP-4, resulting in a half-life of 1 to 2 minutes in the circulation. DPP-4, 
which is located on endothelial cells as well as in soluble form in plasma, cleaves the two N-
terminal amino acids from GLP-1, causing a substantial loss of insulinotropic activity 
(Deacon, 1995; Vahl, 2003). 
GLP-1 stimulates insulin secretion of the ǃ-cells and inhibits glucagon secretion from the ǂ-
cells. Both actions occur in a glucose-dependent manner and lead to a normalisation of 
postprandial and fasting hyperglycaemia (Drucker, 2006b). In the gastrointestinal tract, 
GLP-1 has a direct effect on motility and slows gastric emptying. This effect contributes to a 
normalisation of postprandial hyperglycaemia and explains why long-term treatment with 
GLP-1 receptor agonists leads to weight loss (Drucker, 2006b). Under hypoglycaemic 
conditions the counter-regulation by glucagon is not affected and insulin secretion is not 
stimulated and, therefore, GLP-1 does not elicit hypoglycaemia (Drucker, 2006b).  
Except for its antidiabetic actions, recent findings have shown that application of GLP-1 
receptor agonists led to an improvement in cardiovascular parameters (reduction of systolic 
blood pressure, beneficial effects on myocardial ischaemia in animal models, positive effects 
on left ventricular function in heart failure) (Papazafiropoulou, 2011). In addition, animal 
studies in rodents and isolated human islets showed beneficial long-term actions of GLP-1 
to ǃ-cell mass (Fehmann, 1992; Brubaker, 2004). Whether these findings will have a positive 
effect on preventing T2DM progression is not known yet. 
4. Incretins and the pathogenesis of T2DM 
In T2DM patients the incretin effect is diminished. Incretins does not act as an insulinotropic 
hormones under chronic hyperglycaemia in T2DM. However, GLP-1 is still able to stimulate 
insulin secretion under hyperglycaemia in T2DM (Drucker, 2006). In addition, the effects of 
GLP-1 on gastric emptying and glucagon secretion are maintained in patients with T2DM 
(Nauck, 1993a).  
A study confirmed that the incretin effect is reduced in patients with T2DM (Knop, 2007). 
Another study showed a significant reduction in the incretin effect and the GLP-1 response 
to oral glucose in T2DM patients compared with individuals with normal or impaired 
glucose tolerance (Muscelli, 2008). Notably, impaired actions of GLP-1 may be partially 
restored by improved glycemic control (Knop, 2007). The findings from a study of obese 
diabetic mice suggest that the effect of GLP-1 therapy may be caused by improvements in ǃ-
cell function and insulin sensitivity, as well as by a reduction in gluconeogenesis in the liver 
(Lee, 2007).  
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Several studies in T2DM patients have shown that synthetic GLP-1 administration induces 
insulin secretion, (Nathan, 1992; Nauck, 1993a) slows gastric emptying, and decreases 
inappropriately elevated glucagons secretion (Nauck, 1993a; Kolterman, 2003). Acute GLP-1 
infusion studies showed that GLP-1 improved fasting and post prandial plasma glucose 
concentrations (Nathan, 1992; Nauck, 1993b). Long-term studies showed that this hormone 
exerts euglycemic effects, leading to improvements in HbA1c, and induces weight loss 
(Zander, 2002). 
5. T2DM and incretin-based therapies  
The incretin-based therapies offer a good alternative choice to the established antidiabetic 
compounds due to their satisfying antihyperglycaemic efficacy, their lack of risk of 
hypoglycaemia and their positive effects on body weight. In order to utilise GLP-1 action for 
T2DM, two options are presently available: 
1. GLP-1-receptor agonists (or GLP-1 mimetics) as injectable compounds 
2. DPP-4 inhibitors as orally active substances  
6. GLP-1-receptor agonists 
6.1 Exenatide 
Exenatide is the synthetic form of exendin-4, a peptide first discovered in the saliva of the 
gila monster (heloderma suspectum) in 1992. It has a 53% amino acid sequence homology to 
human GLP-1 and is a GLP-1 receptor agonist (Eng, 1992). It is administered subcutaneously 
twice daily. A slow release formulation for once-weekly administration (Exenatide LAR 
[long-acting release]) is presently in clinical phase III studies (Drucker, 2008). Exenatide has 
a prolonged half-life in comparison to native GLP-1 of approximately 3.5 h. After 
subcutaneous injection sufficient plasma concentrations are reached for 4–6 hours 
(Kolterman, 2005). 
In clinical studies exenatide lowered the HbA1c by 0.8–1.1% (Buse, 2004; DeFronzo, 2005). 
Exenatide in combination with metformin (Kendall, 2005), sulfonylurea (DeFronzo, 2005), or 
both (Buse, 2004) resulted in significant mean HbA1c reductions from baseline ranging from 
–0.77% to –0.86%. Patients also had statistically significant reductions in mean body weight 
from baseline (–1.6 kg to -2.8 kg). Comparative studies with insulin showed that effects of 
exenatide on glycaemic parameters are comparable to the improvement seen with insulin 
therapy (Heine 2005; Gallwitz, 2006; Barnett, 2007; Nauck, 2007). The comparative studies 
with insulin showed a difference in weight development of 4–5 kg in 30 weeks between the 
insulin and exenatide treated groups (Heine 2005; Barnett, 2007a; Nauck, 2007a).  
An improvement of ǃ-cell function [measured with HOMA-ǃ (homeostatic modelling 
assessment of beta cell function) and the proinsulin: insulin ratio] was also observed in the 
clinical studies. First phase of insulin secretion was restored after an intravenous glucose 
bolus under treatment with exenatide (Gallwitz, 2006; Barnett, 2007b).  
Severe hypoglycaemic events were only observed in exenatide-treated patients who had 
received combination therapy with sulfonylurea. For this reason a reduction in the dosage of 
sulfonylurea should be considered when initiating exenatide therapy. In the comparative 
studies comparing exenatide with insulin treatment, the incidence of nocturnal 
hypoglycaemic events was lower in the exenatide-treated patients (Gallwitz, 2006;  
Barnett, 2007).  
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The most frequent adverse events  with exenatide were fullness and nausea. Nausea was the 
most common reason to stop therapy; with 2–6.4% drop-outs in the clinical studies with 
exenatide (Gallwitz, 2006; Barnett, 2007). Escalating the dose of exenatide from 5 μg to 10 μg 
after 4 weeks led to a transient increase in nausea which diminished with continued 
exposure to the higher dose (Gallwitz, 2006; Barnett, 2007).  
In approximately 40% of exenatide-treated patients, anti-exenatide antibodies can be 
detected. However, over a time period of at least 3 years, these antibody titres did not have 
any obvious effect on glycaemic control (Drucker, 2008). Cases of acute pancreatitis have 
been reported since exenatide has been used (Ahmad, 2008; Cure, 2008). In total, the 
incidence of pancreatitis was low and similar to the elevated risk of pancreatitis that was 
observed in obese T2DM patients (Dore, 2009). 
Exenatide is predominantly eliminated by glomerular filtration followed by proteolytic 
degradation (Yoo, 2006). Exenatide should not be used in patients with severe renal 
impairment (creatinine clearance <30 ml/min) or end stage renal disease. Additionally, 
caution should be applied when initiating or increasing doses of exenatide in patients with 
moderate renal impairment (creatinine clearance 30–50 ml/min) (Gallwitz, 2006; Barnett, 
2007). 
6.2 Liraglutide 
Liraglutide is the first human GLP-1 analogue. It has two modifications in the amino acid 
sequence of native GLP-1 and an attachment of a fatty acid side chain to the peptide. It is 
injected subcutaneously once daily (Agerso, 2002). Liraglutide lowers blood glucose, body 
weight and food intake in animal models (Sturis, 2003). In clinical studies in approximately 
4,200 T2DM patients liraglutide was efficacious and safe (Marre, 2009; Nauck, 2009; Zinman, 
2009). In animal studies with diabetic rodents, liraglutide has been shown to increase  
ǃ-cell mass. 
Liraglutide in monotherapy in newly diagnosed T2DM patients led to HbA1c reduction of 
0.9–1.1% in a dose of 1.2 or 1.8 mg once daily respectively, over a period of up to 2 years 
(Garber, 2008). In other studies, the same doses of liraglutide effectively lowered glycaemic 
parameters in various combinations with oral antidiabetic agents by approximately 1.0–1.5% 
(Garber, 2008; Garber, 2009).  
Liraglutide treatment led to a significant weight loss (Deacon, 2009a; Vilsboll, 2009). The 
weight loss was accompanied by a more pronounced loss in visceral fat than subcutaneous 
fat (Deacon, 2009a; Vilsboll, 2009). Furthermore, systolic blood pressure was lowered by 2–6 
mmHg in the liraglutide-treated patients. This effect was independent of the weight loss, as 
the reduction of blood pressure was already observed early on in therapy, when weight loss 
had not yet occurred (Garber, 2008; Garber, 2009; Zinman, 2009).  
The incidence of hypoglycaemic episodes was comparable to placebo in all studies, where 
no sulfonylurea was used in the combination with liraglutide (Deacon, 2009a; Vilsboll, 
2009). Gastrointestinal symptoms were also common, but nausea and vomiting were 
reported for a short period at the beginning of therapy (Buse, 2009). In the liraglutide clinical 
trials, there was no evidence of neutralizing antibodies (Garber, 2008; Garber, 2009;  
Zinman, 2009).  
Animal studies showed that a rare type of thyroid cancer known as medullary thyroid cancer 
was associated with liraglutide in mice and rats, although the relevance of this finding to 
humans remains unknown. FDA has stipulated that liraglutide be contraindicated in patients 
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with a personal or family history of medullary thyroid cancer and in patients with multiple 
endocrine neoplasia syndrome type 2 (US Food and Drug Administration, 2010).  
Data on the pharmacokinetic profile of liraglutide in mild to moderate renal impairment 
showed no alteration of the profile (Deacon, 2009a; Vilsboll, 2009).  
7. DPP-4 Inhibitors 
7.1 Sitagliptin 
Sitagliptin was the first DPP-4 inhibitor approved for the T2DM treatment. The 
recommended dose of once-daily oral sitagliptin is 100 mg. At this dose, sitagliptin can 
inhibit ~80% of endogenous DPP-4 activity over a 24-hour period (Herman, 2005). Increases 
in HOMA-ǃ ranging from 4% to 20% have been shown in the sitagliptin trials. 
In the monotherapy trials, sitagliptin compared to placebo, resulted in statistically significant 
improvements in HbA1c and fasting glucose (Aschner, 2006; Raz, 2006; Scott, 2007). Sitagliptin 
given as add-on therapy to metformin (Charbonnel, 2006) resulted in similar HbA1c and 
fasting glucose reductions as in the monotherapy trials. Τhe same result was observed, in a 24-
week trial, when sitagliptin was added to pioglitazone vs pioglitazone and placebo 
(Rosenstock, 2006). In another study, reductions from baseline in HbA1c and fasting glucose 
were similar when sitagliptin was compared to glipizide, (Nauck, 2007). Increases in HOMA-ǃ 
ranging from 4% to 20% have been shown in the sitagliptin trials. 
Sitagliptin therapy has been shown to be weight neutral in all clinical trials except in one 
study in which sitagliptin given with metformin resulted in weight reduction of 1.5 kg after 
52 weeks of treatment (Nauck, 2007b). The most common side effects of sitagliptin were 
headache, arthritis, nasopharyngitis, respiratory or urinary tract infections and rarely skin 
reactions (Aschner, 2006; Raz, 2006; Rosenstock, 2006). The incidence of hypoglycemia was 
low in these trials (<2%) and was similar to the placebo arms. Dose reduction of sitagliptin 
has been recommended for patients with moderate or severe renal insufficiency or end stage 
renal disease (Bergman, 2007).  
7.2 Vildagliptin 
Vildagliptin also acts by inhibiting circulating DPP-4 activity. It is available as a 50 mg 
twice-daily in combination with metformin, sulfonylurea or pioglitazone. Vildagliptin has 
been studied as monotherapy (Ristic, 2005; Pratley, 2006; Dejager, 2007), in combination 
with other oral antidiabetic agents (Ahren, 2004; Fonseca, 2007; Rosenstock, 2007), and 
against active comparator therapies including glitazones (Rosenstock, 2007) and metformin 
(Schweizer, 2007) Vildagliptin therapy was associated with an increase in HOMA-ǃ (11% 
and 23%) in two monotherapy trials (Ristic, 2005; Pratley, 2006).  
In placebo-controlled trials, vildagliptin monotherapy reduced HbA1c (range 0.5% to 0.9%) 
and fasting glucose (14.4 mg/dL to 19.8 mg/dL) from baseline. The HbA1c reductions 
observed with monotherapy were statistically significantly greater than placebo in all trials. 
In clinical studies testing vildaglitpin in monotherapy or combination therapy with 
metformin, glimepiride, pioglitazone or insulin, vildagliptin was able to decrease the HbA1c 
by approximately 0.5–1.0% (Ahren, 2008; Pratley, 2008; Barnett, 2009). Vildagliptin therapy 
was associated with an increase HOMA-ǃ (11% and 23%) in two monotherapy trials (Ristic, 
2005; Pratley, 2006), but improvement relative to placebo was only observed in one trial 
(Ristic, 2005).  
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Vildagliptin has a good safety and tolerability profile and the most common adverse events 
are flu-like symptoms, headache, dizziness, and rarely liver enzyme elevations. Vildagliptin, 
like the other DPP-4 inhibitors, is weight-neutral. The incidence of hypoglycemia was low in  
trials with vildagliptin and similar to the placebo (Fonseca, 2007; Rosenstock, 2007). No dose 
adjustment is required in patients with mild renal impairment (creatinine clearance 50 
ml/min). Vildagliptin should not be used in patients with hepatic impairment, including 
patients with pre-treatment alanine aminotransferase or aspartate aminotransferase >3x the 
upper limit of normal.  
7.3 Saxagliptin 
Saxagliptin also acts by inhibiting circulating DPP-4 activity and is available as a 5 mg once-
daily in combination with metformin, sulfonylurea or pioglitazone. Saxagliptin causes a 
reduction in HbA1c by 0.7–0.9%. Fasting plasma glucose is also lowered dose dependently 
lowered by saxagliptin (Rosenstock, 2008). In a study with drug-naïve patients, saxagliptin 
lowered all glycaemic parameters significantly (Rosenstock, 2009). As an add-on medication 
to a therapy with either metformin or glitazone, saxagliptin also led to significant metabolic 
improvements (Chacra, 2009; Deacon, 2009b; DeFronzo, 2009).  
Saxagliptin did not cause hypoglycaemia, was well-tolerated and was weight-neutral. A 
meta-analysis of clinical phase III studies with saxagliptin showed favourable data on the 
development of cardiovascular events (Wolf, 2009). 
8. In conclusion 
Incretin-based therapies offer an alternative treatment option for T2DM patients by 
targeting pancreatic ǃ-cell dysfunction. Both GLP-1 receptor agonists and DPP-4 inhibitors 
have been shown to be effective in improving glycemic control in patients with T2DM. They 
appear to be well tolerated, have a low risk of hypoglycaemia, lead to weight reduction or 
have a neutral effect on weight. 
Choice of therapy should be based on a patient’s profile and preference, with consideration 
given to the unique characteristics of the GLP-1 receptor agonists and DPP-4 inhibitors. The 
most patient-relevant and striking difference between the incretin-based therapies is that 
GLP-1 receptor agonists are injectable agents, while DPP-4 inhibitors are effective orally. 
GLP-1 receptor agonists offer more robust HbA1c level reductions and the potential for 
weight loss. Nausea, the most common adverse event observed with GLP-1 receptor agonist 
therapy is not observed in treatment with DPP-4 inhibitors. Advances in the investigation of 
incretin therapies will further improve treatment outcomes for patients with T2DM and help 
them reach target goals. 
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